PMID- 38351731
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240217
IS  - 2228-5806 (Print)
IS  - 2228-5814 (Electronic)
IS  - 2228-5806 (Linking)
VI  - 26
IP  - 1
DP  - 2024 Jan 31
TI  - Fabrication of Rosuvastatin-Incorporated Polycaprolactone -Gelatin Scaffold for 
      Bone Repair: A Preliminary In Vitro Study.
PG  - 70-80
LID - 709206 [pii]
LID - 10.22074/cellj.2023.2009047.1391 [doi]
AB  - OBJECTIVE: Rosuvastatin (RSV) is a hydrophilic, effective statin with a long 
      half-life that stimulates bone regeneration. The present study aims to develop a 
      new scaffold and controlled release system for RSV with favourable properties for 
      bone tissue engineering (BTE). MATERIALS AND METHODS: In this experimental study, 
      high porous polycaprolactone (PCL)-gelatin scaffolds that contained different 
      concentrations of RSV (0 mg/10 ml, 0.1 mg/10 ml, 0.5 mg/10 ml, 2.5 mg/10 ml, 12.5 
      mg/10 ml, and 62.5 mg/10 ml) were fabricated by the thermally-induced phase 
      separation (TIPS) method. Mechanical and biological properties of the scaffolds 
      were evaluated by Fourier transform infrared spectroscopy (FTIR), scanning 
      electron microscope (SEM), compressive strength, porosity, MTT, alkaline 
      phosphatase (ALP) activity, water contact angle, degradation rate, pH alteration, 
      blood clotting index (BCI), and hemocompatibility. RESULTS: SEM analysis 
      confirmed that the porous structure of the scaffolds contained interconnected 
      pores. FTIR results showed that the RSV structure was maintained during the 
      scaffold's fabrication. RSV (up to 62.5 mg/10 ml) increased compressive strength 
      (16.342 +/- 1.79 MPa), wettability (70.2), and degradation rate of the scaffolds. 
      Scaffolds that contained 2.5 mg/10 ml RSV had the best effect on the human 
      umbilical cord mesenchymal stem cell (HUC-MSCs) survival, hemocompatibility, and 
      BCI. As a sustained release system, only 31.68 +/- 0.1% of RSV was released from 
      the PCL-Gelatin-2.5 mg/10 ml RSV scaffold over 30 days. In addition, the results 
      of ALP activity showed that RSV increased the osteogenic differentiation 
      potential of the scaffolds. CONCLUSION: PCL-Gelatin-2.5 mg/10 ml RSV scaffolds 
      have favorable mechanical, physical, and osteogenic properties for bone tissue 
      and provide a favorable release system for RSV. They can mentioned as a a 
      promising strategy for bone regeneration that should be further assessed in 
      animals and clinical studies.
FAU - Gharibshahian, Maliheh
AU  - Gharibshahian M
AD  - Student Research Committee, School of Medicine, Shahroud University of Medical 
      Sciences, Shahroud, Iran.
FAU - Alizadeh, Morteza
AU  - Alizadeh M
AUID- ORCID: 0000-0003-4214-6502
AD  - Department of Tissue Engineering, School of Medicine, Shahroud University of 
      Medical Sciences, Shahroud, Iran.
FAU - Kamalabadi Farahani, Mohammad
AU  - Kamalabadi Farahani M
AD  - Department of Tissue Engineering, School of Medicine, Shahroud University of 
      Medical Sciences, Shahroud, Iran.
FAU - Salehi, Majid
AU  - Salehi M
AUID- ORCID: 0000-0001-6283-8181
AD  - Department of Tissue Engineering, School of Medicine, Shahroud University of 
      Medical Sciences, Shahroud, Iran. Email: Salehi.m@shmu.ac.ir.
AD  - Tissue Engineering and Stem Cells Research Centre, Shahroud University of Medical 
      Sciences, Shahroud, Iran.
AD  - Sexual Health and Fertility Research Centre, Shahroud University of Medical 
      Sciences, Shahroud, Iran.
LA  - eng
PT  - Journal Article
DEP - 20240131
PL  - Iran
TA  - Cell J
JT  - Cell journal
JID - 101566618
PMC - PMC10864776
OTO - NOTNLM
OT  - Bone
OT  - Gelatin
OT  - Polycaprolactone
OT  - Regeneration
OT  - Rosuvastatin
EDAT- 2024/02/14 06:43
MHDA- 2024/02/14 06:44
PMCR- 2024/01/01
CRDT- 2024/02/14 02:43
PHST- 2023/08/11 00:00 [received]
PHST- 2024/02/14 06:44 [medline]
PHST- 2024/02/14 06:43 [pubmed]
PHST- 2024/02/14 02:43 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 709206 [pii]
AID - 10.22074/cellj.2023.2009047.1391 [doi]
PST - epublish
SO  - Cell J. 2024 Jan 31;26(1):70-80. doi: 10.22074/cellj.2023.2009047.1391.